MX2007003062A - Composicion de permucosa y metodo de mejorar la absorcion de permucosa. - Google Patents
Composicion de permucosa y metodo de mejorar la absorcion de permucosa.Info
- Publication number
- MX2007003062A MX2007003062A MX2007003062A MX2007003062A MX2007003062A MX 2007003062 A MX2007003062 A MX 2007003062A MX 2007003062 A MX2007003062 A MX 2007003062A MX 2007003062 A MX2007003062 A MX 2007003062A MX 2007003062 A MX2007003062 A MX 2007003062A
- Authority
- MX
- Mexico
- Prior art keywords
- mucosa
- permucosal
- composition
- improving
- absorption
- Prior art date
Links
- 238000010521 absorption reaction Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 210000004877 mucosa Anatomy 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 abstract 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 abstract 1
- 210000001156 gastric mucosa Anatomy 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 229960002442 glucosamine Drugs 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 210000002850 nasal mucosa Anatomy 0.000 abstract 1
- 238000006116 polymerization reaction Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004268891 | 2004-09-15 | ||
| PCT/JP2005/016739 WO2006030730A1 (ja) | 2004-09-15 | 2005-09-12 | 経粘膜用組成物、及び経粘膜吸収の向上方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007003062A true MX2007003062A (es) | 2007-05-21 |
Family
ID=36059983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007003062A MX2007003062A (es) | 2004-09-15 | 2005-09-12 | Composicion de permucosa y metodo de mejorar la absorcion de permucosa. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080075691A1 (https=) |
| EP (1) | EP1790351A4 (https=) |
| JP (1) | JPWO2006030730A1 (https=) |
| KR (1) | KR20070057932A (https=) |
| CN (1) | CN101018560A (https=) |
| AR (1) | AR050937A1 (https=) |
| AU (1) | AU2005283512A1 (https=) |
| BR (1) | BRPI0515301A (https=) |
| CA (1) | CA2577336A1 (https=) |
| MX (1) | MX2007003062A (https=) |
| RU (1) | RU2007114068A (https=) |
| TW (1) | TW200612975A (https=) |
| WO (1) | WO2006030730A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2885621C (en) * | 2007-03-30 | 2016-01-05 | Hirofumi Takeuchi | Transpulmonary liposome for controlling drug arrival |
| CA2716565C (en) * | 2008-02-28 | 2017-09-12 | Toray Industries, Inc. | Pharmaceutical composition for transnasal administration |
| JPWO2011142484A1 (ja) * | 2010-05-14 | 2013-07-22 | 株式会社日本触媒 | ポリアルキレンイミンを含むウイルス感染症治療薬 |
| WO2018135543A1 (ja) | 2017-01-19 | 2018-07-26 | 国立大学法人島根大学 | 腸粘膜の透過性の診断薬、診断方法、診断装置 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1261264A (en) * | 1984-11-29 | 1989-09-26 | Shigeo Suzuki | Immunopotentiating agents and method |
| GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| US6184037B1 (en) * | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
| EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| JPH11116499A (ja) * | 1997-10-16 | 1999-04-27 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有した経口投与用ナノスフェア |
| GB9725084D0 (en) * | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| JP3041799B1 (ja) * | 1998-09-29 | 2000-05-15 | 株式会社微生物化学研究所 | 新規なアジュバント及びそれを用いたワクチン |
| US6333304B1 (en) * | 1999-04-20 | 2001-12-25 | Teresa K. Bath | Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue |
| IL131074A0 (en) * | 1999-07-23 | 2001-03-19 | Polygene Ltd | A biodegradable polycation composition for delivery of an anionic macromolecule |
| US6773723B1 (en) * | 2000-08-30 | 2004-08-10 | Depuy Acromed, Inc. | Collagen/polysaccharide bilayer matrix |
| WO2002034287A2 (en) * | 2000-10-27 | 2002-05-02 | Pharmexa A/S | Therapeutic vaccine formulations containing chitosan |
| NO317654B1 (no) * | 2002-05-03 | 2004-11-29 | Stiftelsen Biopolymer | Formulering som inneholder en nukleinsyre og et kitosan, fremgangsmate for fremstilling av formuleringen, samt anvendelser derav. |
| DE102004040243A1 (de) * | 2003-08-22 | 2005-03-17 | Heppe, Katja, Dipl.-Biotechnol. | Transportsystem auf Chitosanbasis |
| GB0403938D0 (en) * | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
-
2005
- 2005-09-12 KR KR1020077008268A patent/KR20070057932A/ko not_active Ceased
- 2005-09-12 AU AU2005283512A patent/AU2005283512A1/en not_active Abandoned
- 2005-09-12 CN CNA2005800308628A patent/CN101018560A/zh active Pending
- 2005-09-12 WO PCT/JP2005/016739 patent/WO2006030730A1/ja not_active Ceased
- 2005-09-12 RU RU2007114068/15A patent/RU2007114068A/ru not_active Application Discontinuation
- 2005-09-12 BR BRPI0515301-8A patent/BRPI0515301A/pt not_active IP Right Cessation
- 2005-09-12 US US11/662,094 patent/US20080075691A1/en not_active Abandoned
- 2005-09-12 MX MX2007003062A patent/MX2007003062A/es unknown
- 2005-09-12 EP EP05782391A patent/EP1790351A4/en not_active Withdrawn
- 2005-09-12 JP JP2006535871A patent/JPWO2006030730A1/ja active Pending
- 2005-09-12 CA CA002577336A patent/CA2577336A1/en not_active Abandoned
- 2005-09-14 TW TW094131630A patent/TW200612975A/zh not_active IP Right Cessation
- 2005-09-15 AR ARP050103852A patent/AR050937A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070057932A (ko) | 2007-06-07 |
| RU2007114068A (ru) | 2008-10-27 |
| AU2005283512A1 (en) | 2006-03-23 |
| WO2006030730A1 (ja) | 2006-03-23 |
| EP1790351A4 (en) | 2009-11-04 |
| JPWO2006030730A1 (ja) | 2008-05-15 |
| CN101018560A (zh) | 2007-08-15 |
| BRPI0515301A (pt) | 2008-07-15 |
| TWI291874B (https=) | 2008-01-01 |
| TW200612975A (en) | 2006-05-01 |
| US20080075691A1 (en) | 2008-03-27 |
| EP1790351A1 (en) | 2007-05-30 |
| EP1790351A8 (en) | 2007-10-10 |
| AR050937A1 (es) | 2006-12-06 |
| CA2577336A1 (en) | 2006-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7166575B2 (en) | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity | |
| ES2365648T3 (es) | Administración oral de una calcitonina. | |
| WO2004003145A2 (en) | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds | |
| WO2003000018A2 (en) | Dopamine agonist formulations for enhanced central nervous system delivery | |
| RU2011126239A (ru) | Фармацевтическая композиция, составленная для локального нанесения на поверхность барьера эпителиальной ткани, содержащая антитела, которые проходят через этот барьер | |
| JP2009537143A5 (https=) | ||
| RU2009111391A (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ | |
| WO2002043746A3 (en) | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension | |
| WO2003079993A3 (en) | hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION | |
| WO2003040398A3 (en) | Proteins stabilized with polysaccharide gums | |
| WO2003028757A1 (en) | Novel method of inducing antigen-specific t cells | |
| WO2006023665A3 (en) | Il-1 antagonist formulations | |
| AU2018360382A1 (en) | Oral delivery of GLP-1 peptide analogs | |
| RU2012118376A (ru) | Полимерное связующее вещество, композиция, включающая полимерное связующее вещество, и применение указанного полимерного связующего вещества | |
| TW200612975A (en) | Permucosal composition and method of improving permucosal absorption | |
| WO2003037272A3 (en) | Thymosin alpha 1 peptide/polymer conjugates | |
| DK168273B1 (da) | Anvendelse af cyclopeptidhjælpestoffer eller fysiologisk acceptable salte deraf som resorptionsfremmende stoffer af peptider og proteiner ved påføring på slimhinder samt farmaceutisk præparat indeholdende disse hjælpestoffer og fremgangsmåde til fremstilling af præparatet | |
| SE0401631L (sv) | Ny sammansättning | |
| JP2025504049A5 (https=) | ||
| Bayley et al. | The Transmucosal Absorption of Recombinant Human Interferon‐α B/D Hybrid in the Rat and Rabbit | |
| US20230218727A1 (en) | Thrombin c-terminal peptides to treat corona viral infections | |
| CA3180205A1 (en) | Use of surfactant protein d to treat viral infections | |
| WO2021191904A1 (en) | Methods for preventing and treating viral infection | |
| WO2004023979A3 (en) | Mucus formulation for mucosal surfaces and uses thereof | |
| JP2025506427A (ja) | 生物学的製剤の経口送達のための組成物 |